Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GlaxoSmithKline PLC (OTC Pink - Current Information:GLAXF)

Delayed Data
As of Jun 23
 -0.80 / -3.58%
Today’s Change
Today|||52-Week Range
Glaxo's (GSK) Shingles Candidate Phase III Data Positive
Jun 22 / Zacks.com - Paid Partner Content
Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now?
Jun 16 / Zacks.com - Paid Partner Content
Novartis Announces Positive Results for Cardiovascular Drug
Jun 22 / Zacks.com - Paid Partner Content
Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval
Jun 15 / Zacks.com - Paid Partner Content
VBI Vaccines Just Took a Major Step Forward in Its HBV Program
Jun 21 / GuruFocus News - Paid Partner Content
Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen
Jun 13 / Zacks.com - Paid Partner Content
Novartis (NVS) Biosimilar of MabThera Approved in the EU
Jun 19 / Zacks.com - Paid Partner Content
Novartis Presents Positive Data on CAR-T Cell Therapy Drug
Jun 12 / Zacks.com - Paid Partner Content
GlaxoSmithKline's Benlysta Positive in Continuation Trial
Jun 19 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close22.35
Today’s open21.55
Day’s range21.55 - 21.55
Average volume (3 months)2,236
Market cap$106.0B
Dividend yield4.80%
Data as of 9:30am ET, 06/23/2017

Growth & Valuation

Earnings growth (last year)-90.47%
Earnings growth (this year)--
Earnings growth (next 5 years)--
Revenue growth (last year)+2.96%
P/E ratio--


No competitors data available.


Next reporting date--
EPS forecast (this quarter)--
Annual revenue (last year)$37.6B
Annual profit (last year)$1.2B
Net profit margin3.27%


Health Technology
Pharmaceuticals: Major
Chief Executive Officer &
Executive Director
Emma Walmsley
Chief Financial Officer &
Executive Director
Simon Dingemans
Corporate headquarters
Brentford, Greater London